{"Symbol": "ASNS", "AssetType": "Common Stock", "Name": "Actelis Networks Inc.", "Description": "Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to treat infectious diseases. The company is headquartered in Waltham, Massachusetts.", "CIK": "1141284", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "TECHNOLOGY", "Industry": "COMMUNICATION EQUIPMENT", "Address": "4039 CLIPPER COURT, FREMONT, CA, UNITED STATES, 94538-6540", "OfficialSite": "https://actelis.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "1867100", "EBITDA": "-7190000", "PERatio": "None", "PEGRatio": "None", "BookValue": "1.698", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-8.4", "RevenuePerShareTTM": "3.663", "ProfitMargin": "-2.239", "OperatingMarginTTM": "-3.114", "ReturnOnAssetsTTM": "-0.575", "ReturnOnEquityTTM": "-2.601", "RevenueTTM": "3367000", "GrossProfitTTM": "1103000", "DilutedEPSTTM": "-8.4", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "-0.747", "AnalystTargetPrice": "5", "AnalystRatingStrongBuy": "0", "AnalystRatingBuy": "1", "AnalystRatingHold": "0", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "0.554", "PriceToBookRatio": "0.63", "EVToRevenue": "0.352", "EVToEBITDA": "-0.66", "Beta": "2.111", "52WeekHigh": "12.9", "52WeekLow": "0.22", "50DayMovingAverage": "0.894", "200DayMovingAverage": "4.3", "SharesOutstanding": "8058400", "SharesFloat": "1579800", "PercentInsiders": "14.630", "PercentInstitutions": "4.077", "DividendDate": "None", "ExDividendDate": "None"}